Managing Autoimmune Skin Disease in Pregnancy and Lactation: Case-Based Treatment Considerations

Conclusions

• Most women with autoimmune and inflammatory skin disease can achieve good pregnancy outcomes when disease control is optimized before conception and treatment is not inappropriately stopped.
• The safest strategy is usually to balance the risks of medication against the risks of uncontrolled disease, since untreated flares can be more harmful to both mother and fetus than many continued therapies.
• Pregnancy-compatible medications such as hydroxychloroquine, azathioprine, steroids, IVIG, tacrolimus, cyclosporine, and many biologics can often be continued when clinically necessary.
• For severe diseases like dermatomyositis and lupus, higher-risk or newer agents may still be reasonable in selected cases if they are the only effective way to control disease and available data do not show a clear safety signal.
• Reliable pregnancy counseling depends on using strong evidence sources such as Reprotox and LactMed rather than assuming all medication warnings are equally supported.
• Active lupus is one of the highest-risk autoimmune diseases in pregnancy, and remission on pregnancy-compatible therapy for several months before conception is a major goal.
• Stopping effective therapy during pregnancy can precipitate flares, fetal loss, growth restriction, preeclampsia, or maternal complications, so medication discontinuation is often the biggest avoidable risk.
• Placental transfer does not automatically mean fetal harm, and many concerns are more about timing, organogenesis, growth effects, and disease activity than simple exposure alone.
• Breastfeeding should be viewed as part of maternal-infant health rather than an afterthought, because lactation has measurable long-term benefits for both mother and baby.
• Many medications are compatible with breastfeeding, especially large injected or infused biologics that transfer poorly into milk and are unlikely to be absorbed by the infant.
• When medication is needed during pregnancy or lactation, the preferred approach is the lowest effective dose with the fewest medications, while maintaining adequate disease control.
• Counseling reproductive-age patients about contraception and teratogenic medications is essential because unplanned pregnancy is common and patients may misunderstand medication warnings.